Condensed azines for ep300 or cbp modulation and indications therefor
US2019300487A1
Compounds and methods for ido and tdo modulation, and indications therefor
CN112165958A
Formulations of compounds for modulating kinases
EP3694855A1
Solid forms of a compound for modulating kinases
US2018354946A1
Compounds and methods for kinase modulation
AU2018237047A1
Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1H- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain
CA3047580A1
Compounds and methods for cdk8 modulation and indications therefor
TW201815766A
Compounds and methods for IDO and TDO modulation, and indications therefor
US2017267660A1
Compounds and methods for kinase modulation, and indications therefor
US2017158690A1
Compounds and methods for kinase modulation, and indications therefor
MX2018003432A
Heterocyclic compounds and uses thereof.
US2017029413A1
Compounds and methods for kinase modulation, and indications therefor
EP3297630A1
Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases
TW201713652A
Synthesis of heterocyclic compounds
CN107548394A
Adjust the solid form of the compound of kinases
CA2984899A1
Synthesis of 1 h-pyrrolo[2,3-b]pyridin derivatives that modulate kinases
US2016326162A1
Compounds and methods for kinase modulation, and indications therefor
AU2015268769A1
Kinase modulation and indications therefor
AU2015318233A1
Heterocyclic compounds and uses thereof
AU2015207857A1
Pyrrolo [2,3-B] pyridine derivatives as protein kinase inhibitors
